Results 191 to 198 of about 3,283 (198)

Vitritis following intravitreal faricimab: a retrospective monocentric analysis

Graefe's Archive for Clinical and Experimental Ophthalmology
Alexandre Bourdin, S. Y. Cohen, S. Nghiem-Buffet, Jérôme Smadja, M. Paques, F. Fajnkuchen, Sarah Mrejen   +6 more
semanticscholar   +1 more source

Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab

Ophthalmology Retina
Michael Grinton, Raffaele Raimondi, David H W Steel   +2 more
exaly  

Efficacy of treatment with faricimab for patients with refractory nAMD

European Journal of Ophthalmology
Sajjad Mahmood, Clare O'Donnell
exaly  

One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration

Japanese Journal of Ophthalmology
H. Matsumoto, Junki Hoshino, Kosuke Nakamura, Hideo Akiyama   +3 more
semanticscholar   +1 more source

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in diabetic macular edema: 2-year results from the Japan subgroup of the phase 3 YOSEMITE trial

Japanese Journal of Ophthalmology
Masahiko Shimura, Yoshinori Mitamura, Shigehiko Kitano   +2 more
exaly  

Global experience of faricimab in clinical settings - a review

Expert Opinion on Biological Therapy
Nilesh Kumar, Anat Loewenstein, Francesco Bandello   +2 more
exaly  

Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmology Retina
Michael A Klufas, Allen Chiang, Asad F Durrani   +2 more
exaly  

Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab

Ophthalmology Retina
Praveen J Patel, Sobha Sivaprasad, Evangelia Chalkiadaki   +2 more
exaly